Lupin inks research and development pact with Medicis

25 Jul 2011 Evaluate

Lupin has entered into a research and development pact with Medicis Pharmaceutical Corporation to apply proprietary Lupin formulation technologies to multiple therapeutic compounds.

Under the terms of the agreement, Lupin will receive a $20 million upfront payment from Medicis and will be primarily responsible for formulating certain novel therapeutic products for Medicis, utilizing several of Lupin’s formulation technologies. 

Lupin an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs. The company today has significant presence in Cardiovascular (prils and statins), Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infective and NSAIDs in addition to holding global leadership positions in the Anti-TB and Cephalosporins space.

Lupin Share Price

2147.55 -14.65 (-0.68%)
20-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.50
Dr. Reddys Lab 1342.45
Cipla 1472.45
Lupin 2147.55
Zydus Lifesciences 973.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.